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encapsulation boosts islet-cell 
signature in differentiating human 
induced pluripotent stem cells via 
integrin signalling
Thomas Aga Legøy1,7, Heidrun Vethe1,7, Shadab Abadpour2,3, Berit L. Strand4, 
Hanne Scholz2,3, Joao A. paulo5, Helge Ræder1,6, Luiza Ghila  1 & Simona chera  1*
Cell replacement therapies hold great therapeutic potential. Nevertheless, our knowledge of the 
mechanisms governing the developmental processes is limited, impeding the quality of differentiation 
protocols. Generating insulin-expressing cells in vitro is no exception, with the guided series of 
differentiation events producing heterogeneous cell populations that display mixed pancreatic islet 
phenotypes and immaturity. The achievement of terminal differentiation ultimately requires the  
in vivo transplantation of, usually, encapsulated cells. Here we show the impact of cell confinement 
on the pancreatic islet signature during the guided differentiation of alginate encapsulated human 
induced pluripotent stem cells (hiPSCs). Our results show that encapsulation improves differentiation 
by significantly reshaping the proteome landscape of the cells towards an islet-like signature. Pathway 
analysis is suggestive of integrins transducing the encapsulation effect into intracellular signalling 
cascades promoting differentiation. These analyses provide a molecular framework for understanding 
the confinement effects on hiPSCs differentiation while confirming its importance for this process.
Differentiation of human pluripotent stem cells (hPSCs) into fully developed cell types holds a great therapeutic 
potential, especially the generation of hPSC-derived insulin-producing cells for cell therapy of diabetes. In mam-
mals, pancreatic adult islets contain four hormone-secreting endocrine cell populations, each secreting only one 
specific hormone: insulin (β-cells), glucagon (α-cells), somatostatin (δ-cells), pancreatic polypeptide (PP-cells, 
γ-cells) and ghrelin (ε-cells). Multistep-protocols that mimic pancreas development have been designed for the 
generation of hPSC-derived insulin-expressing cells in vitro1–3.
Despite an increasing number of differentiation protocols, the efficient generation of a stable mature and 
functional insulin-producing β-cell is yet to be convincingly achieved4,5. Moreover, most of these proto-
cols do not restrict the cells towards β-cell fate exclusively, but rather generate cell entities resembling diverse 
hormone-secreting islet cell types. At final stages of differentiation, the generated cell populations are highly het-
erogeneous, with cells displaying variable levels or absence of key β-cell markers (such as PDX1 and NKX6.1) and 
a polyhormonal profile, resembling the transient endocrine cells observed in the fetal pancreas6,7. Nevertheless, 
the reported heterogeneity grants certain advantages, as increasing evidence indicates that efficient glucose regu-
lation requires proper arrangement and coordination between the various endocrine cell types found within the 
islets8,9. Therefore, recent research suggested focusing on in vitro generation of islets (i.e. all five cell populations) 
rather than aiming at differentiating cells into a single type of specialized cells10.
Currently, the final steps of β-cell maturation are achieved in vivo, by transplantation into mammalian hosts, 
such as mice. The cellular and molecular basis of the process driving this in vivo terminal differentiation is not yet 
completely understood11. Different potential scenarios include the involvement of circulating factors12–15, nervous 
system association16–18 and the presence of a 3D niche19,20, amongst others. Discriminating the exact contribution 
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of each of these potential scenarios on the transplanted hPSC-derived cells is difficult due to the inherent com-
plexity of the organism environment.
Microencapsulation of islets into alginate microbeads was used first in the 1980s21, and was later employed 
in several studies for transplantation of pancreatic islets22–25. Previous studies have reported that entrapment of 
hPSCs under the 3D environment of alginate microcapsules26 supports long-term maintenance of pluripotency27 
and differentiation of dopamine neurons28, as well as pancreatic progenitors29. Alginate is recognized for proper-
ties and characteristics such as its ability to make hydrogels at physiological conditions, transparency for micro-
scopic evaluation, gel pore network that allows diffusion of nutrients and waste materials30, making alginate an 
attractive alternative for embedding hPSC-derived cells during differentiation.
In this study, we differentiated hiPSCs (human induced pluripotent stem cells) towards β-like cells follow-
ing a seven-stage protocol1, as we have reported previously31, to assess the impact of alginate encapsulation on 
islet cell differentiation potential during in vitro differentiation. Our data indicate that encapsulation of pancre-
atic endocrine progenitor efficiently improves the differentiation outcome by increasing both the proportion of 
hormone-positive cells and the fraction of insulin cells co-expressing key β-cell markers. Moreover, encapsulation 
enables proteome adaptations of the differentiating cells towards a more islet-like fingerprint in a stage-specific 
manner, where the encapsulation of the first differentiation stages promotes early differentiation signals, while 
the encapsulation at a later differentiation stage promotes hormones and factors involved in hormone synthesis 
and secretion. Our results further suggest that these effects of alginate are relayed through integrins, which pre-
sumably translate the pressure elicited by the confinement of cells in the alginate matrix into signalling cascades.
Results
Encapsulation promotes the expression of islet hormones and key islet transcriptional regu-
lators. To investigate whether encapsulation had an impact on the differentiation outcome, we differentiated 
cells either on Matrigel-coated plates (representing a classical 2D culture condition) or encapsulated in alginate 
(representing a 3D platform for differentiation). Due to its high reproducibility and feasibility, we selected one of 
the most commonly employed protocol for β-cell differentiation designed by Rezania et al.1, where hiPSC cells are 
differentiated gradually through a sequence of events involving 7-stages (Supp. Fig. 1a).
The dissociated cells before encapsulation displayed a viability of 90.96% ± 5.6, presenting homogeneous cell 
morphologies and no signs of proliferation or cluster formation within the alginate beads. Sporadic clumps of cells 
escaping the dissociating procedure were observed, however these did not present an ulterior different behaviour 
compared to single cells (Supp. Fig. 1b,c). The alginate beads, presenting a radius of 375–500 µm, were processed for 
immunofluorescence (IF) and high magnifications of whole mount encapsulated cells (Supp. Fig. 1c) and sections 
(Supp. Fig. 1d) revealed spherical cell morphology typical of single cells in suspension. To allow the quantification 
of the largest possible bead volume, we imaged for each whole mount bead a mosaic of 3 × 3 fields of view (FOV) 
over 100 different focal planes and performed a 3D reconstruction (Supp. Fig. 1e,f). Due to the large amount of data 
generated and also for excluding any potential counting-bias, we performed automatic quantification using Imaris 
9.1.2 with the program being supervised by manual counting of randomly chosen FOV.
Cells were encapsulated: (1) at the beginning of the protocol (hiPSC stage [S0]) and differentiated in alginate 
capsules until Stage 7 (hereafter termed S7bead[S0-S7]), (2) during the last two stages of the differentiation protocol, 
i.e. end of Stage 5 (corresponding to pancreatic endocrine progenitors) until Stage 7 (hereafter termed S7bead[S5-S7]) 
as well as (3) at the final stage of the differentiation protocol, just before fixation, for consistency of imaging and 
counting (hereafter termed S7bead[S7]) (Fig. 1a, Supp. Fig. 1a,b).
We first assessed the variation in the proportion of insulin-, glucagon-, and somatostatin-expressing cells 
following encapsulation (Fig. 1b,c,f, Supp. Fig. 2a). A highly significant increase in the proportion of cells express-
ing insulin, glucagon, and somatostatin was observed when cells were encapsulated at the later stages of dif-
ferentiation (S7bead[S5-S7]) as compared to the ones grown on Matrigel-coated plates (S7bead[S7]). The number of 
bihormonal cells was not significantly affected by encapsulation (Fig. 1c). Interestingly, the cells encapsulated 
during the entire period of differentiation (S7bead[S0-S7]) displayed a significant increase of the glucagon- and 
somatostatin-expressing cell populations, but not insulin, as previously reported29.
We further assessed in all three conditions analysed the expression of the β-cells transcriptional regulators 
PDX1 and NKX6.1 (Fig. 1d,e,g, Supp. Fig. 2b), two key factors involved in early pancreas development, endocrine 
compartment differentiation and β-cell fate32–34. Consistent with the previous results, the highest increase in 
the proportion of the PDX1- and NKX6.1-expressing cells was observed in the S7bead[S5-S7] population (63.97%, 
Fig. 1c,e). The proportion of PDX1-expressing cell population was significantly decreased in the S7bead[S0-S7] 
(36.7%) when compared to the S7bead[S7] population differentiated in 2D (49.53%), while the proportion of 
NKX6.1-expressing cells was not significantly different. Despite the higher proportion of PDX1-expressing cells, 
only a very low number of the insulin-positive cells of S7bead population co-expressed PDX1 (27.89%) and even 
fewer (19.19%) co-expressed NKX6.1 (Fig. 1e,g, Supp. Fig. 2b) indicating the presence of (1) a large fraction of 
insulin-expressing cells missing these key factors for their functionality and stability as well as (2) a considerable, 
probably immature, insulin-negative subpopulation of PDX1 + and NKX6.1 + cells.
In contrast, despite the lower proportion of PDX1-expressing cells, the S7bead[S0-S7] had a higher proportion of 
insulin-positive cells co-expressing PDX1 (43.33%) as well as NKX6.1 (59.44%). The best expression overlap was 
identified once more in the population of cells encapsulated during the last two stages of differentiation (S7bead[S5-S7]) 
with 72.25% of the insulin + cells co-expressing PDX1 and 60.04% co-expressing NKX6.1 (Fig. 1e,g, Supp. Fig. 2b).
Overall, these data indicate that encapsulation during the last stages of differentiation (i.e. from the pancre-
atic endocrine progenitor stage [S5]) improves the differentiation outcome by increasing both the proportion of 
hormone-positive cells and the fraction of insulin cells co-expressing key β-cell markers. Interestingly, encap-
sulation during the entire length of differentiation seem to improve the insulin cells profile quality rather than 
increasing their numbers.
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Encapsulation promotes a large battery of proteins towards islet-like abundance levels. To 
comprehensively assess the encapsulation effect on the differentiation outcome, in a parallel and independent 
set of experiments, we performed global proteomics on differentiating hiPSC cells, which were grown either 
Figure 1. Comparison of the hiPSC differentiation outcome according to the stage of encapsulation. (a) Scheme 
depicting the three cell populations analysed by immunofluorescence. (b) Proportion of the differentiated 
hiPSC-cells expressing insulin, glucagon or somatostatin in the three distinct populations analysed, quantified 
by Imaris software. (c) Proportion of bihormonal cells in the three distinct populations analyzed. (d) Proportion 
of the differentiated hiPSC-cells expressing PDX1 or NKX6.1 in the three distinct populations analysed.  
(e) Proportion of insulin + cells coexpressing PDX1 or NKX6.1. (f) High magnification confocal images of 
cells inside alginate capsules stained for insulin (green), glucagon (red), somatostatin (purple) and DAPI (blue) 
by whole mount immunofluorescence. (g) Whole mount immunofluorescence of encapsulated cells stained 
for insulin (green), NKX6.1 (red), PDX1 (purple) and DAPI (blue), gamma correction 0.4. Scale bars: 10 µm. 
Graphs data are shown as mean ± SEM.
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on Matrigel-coated plates (2D) or encapsulated in alginate (3D). To allow the investigation of the observed 
stage-dependent encapsulation effect, the cells were differentiated in capsules during (1) the early stages of differ-
entiation (from the iPSC stage [S0] to the pancreatic endocrine progenitor [S5], hereafter termed S5bead[S0-S5]) and 
(2) the late stages of differentiation (from the pancreatic progenitor stage [S5] to maturing β-like cell [S7], hereaf-
ter termed S7bead[S5-S7]) (Fig. 2a). These, their Matrigel-differentiating counterparts (S5 and S7) and native human 
islets isolated from deceased donors were compared by TMT 11-plex-based quantitative proteomics (Fig. 2b). We 
quantified a total of 5364 proteins and focused our analysis on the proteins expressed in at least one sample of 
each condition (5029 proteins).
The hierarchical clustering revealed that encapsulated samples (S5bead[S0-S5] and S7bead[S5-S7]) cluster closer to 
the human islets than their 2D culture condition differentiation-stage counterparts, with the S7bead[S5-S7] samples 
being nearest (Fig. 2c). These data suggest that encapsulation globally enhances the pancreatic endocrine cell fate, 
reinforcing the initial IF results.
Unfortunately, due to the inherent sensitivity limitation of the proteomics methods, we were unable to detect 
proteins with very low abundance, as displayed by many key pancreatic islet transcription factors, such as PDX1 
or NKX6.1. Nevertheless, in consensus with our previous IF characterization, we observed a steep increase of all 
pancreatic islet hormones following encapsulation (Supp. Fig. 3a).
We further aimed to identify the proteins modulated towards an islet-like regulation in response to 
encapsulation. A simple comparison analysis between cells differentiating in capsules and their 2D culture 
counterparts would provide information about the general effects of encapsulation, but would fall short in 
identifying proteins relevant for differentiation towards islet cell phenotypes. Consequently, to discriminate the 
differentially-expressed proteins (DEPs) that in response to encapsulation are changing their abundance pro-
files towards the levels detected in islets from those with opposite regulation, we introduced the islet samples 
as normalization. We first filtered 3740 DEPs (FC ≥ 1.5 p < 0.05) between S5-cells and islets (Supp. Table 1), 
containing many key islet cell markers, which differential regulation was also confirmed at gene expression levels 
(Supp. Fig. 3b). Subsequently, we assessed this 3740 DEPs set regulation dynamics in response to the differ-
ent conditions (Fig. 2d, outlined in Supp. Fig. 3b): (1) stages of the differentiation protocol (S7/Islet, hereafter 
termed “Differentiation Cocktail Effect”), (2) encapsulation during early stages of differentiation (S5bead[S0-S5]/
Islet, hereafter termed “Early Encapsulation Effect”) and (3) differentiation cocktail combined with late encap-
sulation (S7bead[S5-S7]/Islet, hereafter “Confounding Effect”). Following the same rationale, a second 3958 DEPs 
list (FC ≥ 1.5 p < 0.05) was generated between S7-cells and islets (S7/Islets, Supp. Table 1) and their regulatory 
dynamics in response to (4) encapsulation during later stages of differentiation was assessed (S7bead[S5-S7]/Islet, 
hereafter termed “Late Encapsulation Effect”) (Fig. 2d, Supp. Fig. 3c). As before, this DEP category included many 
key islet cell markers with confirmed differential expression some of which presented in Supp. Fig. 3d.
We categorized the DEPs according to their response to each of the above effects (up- or downregulated, 
FC ≥ 1.5 compared to their initial level of regulation in S5/Islet or S7/Islet, respectively, Fig. 2e, Supp. Fig. 3e). The 
upregulated DEPs (S5/Islet or S7/Islet), which decrease their abundance towards islet expression levels following 
a certain effect (differentiation cocktail, early encapsulation, confounding) present an islet-promoting regulation 
(Fig. 2e, upper row). Following the same rationale, downregulated DEPs that show a tendency to recover towards 
islet expression levels will fall into the same category (Fig. 2e, lower row). In contrast, proteins that respond by 
drifting away from the islet abundance levels, will display an islet-antagonizing regulation (Supp. Fig. 3c). The 
number of proteins with an islet-promoting regulation was steeply increased in response to encapsulation when 
compared with the effect of the differentiation cocktail, regardless of the time of alginate encapsulation (Fig. 2e,f). 
Most of these proteins (83%, 81%, 73.8%, depending on the effect) presented a pattern of regulation characterized 
by high abundance in S5- or S7-cells as compared with islets, which decreased towards islet expression levels 
upon encapsulation (Fig. 2e, compare red and green bars of the last three effects).
Furthermore, the number of proteins reaching abundance values similar to those exhibited by native islets was 
also increased by encapsulation, from 7.51% regulated in response to the differentiation cocktail alone to 21.71%, 
27.67% and 27.18% when encapsulation influence was considered (Fig. 2f, Supp. Table 2). Of note, the number of 
proteins presenting an islet-antagonizing pattern was decreasing in the three effects assessing the encapsulation 
involvement (Fig. 2f dark grey sectors, Supp. Fig. 3c).
Overall, these results suggest that, regardless of the iPSC differentiation stage, encapsulation was able to sub-
stantially modify the proteome landscape towards a more islet-like fingerprint, mostly by either maintaining 
or promoting lower abundance levels of certain proteins, which otherwise display an upregulated pattern in 
2D-differentiated cells.
Pathway analysis reveals common proteome signatures in response to encapsulation. To 
identify the protein networks, signalling pathways and upstream regulators characterizing the improved 
islet-signature of the encapsulated differentiating cells in each of the four effects described above, we performed 
pathway analysis on the protein sets exhibiting islet-promoting regulation (Fig. 3, Supp. Fig. 4a,c,e,g, Supp. 
Table 2). As a further refinement, we repeated the analysis on the protein sets reaching islet-like abundance levels 
in each dataset (Supp. Fig. 4b,d,f,h).
IPA (Ingenuity Pathway Analysis software) revealed that the protein set exhibiting an islet-promoting pattern 
of regulation in response to the differentiation cocktail (Differentiation Cocktail Effect) was consistent with the 
expected outcome of the typical stage progression of differentiating cells (Fig. 3a,b, Supplemental Fig. 4a). The 
Tight Junction Signaling, several metabolic pathways and IGF-1 Signaling were identified in the top canonical 
pathways, the latter being predicted as activated in S7-cells (Fig. 3a). The program selected the cell-cycle regu-
lators TP53, MYC, KRAS as well as the key developmental pancreatic islet cell marker HNF4A and the insu-
lin trafficking regulator MAPT (TAU protein) in the Top 5 predicted upstream regulators responsible for the 
observed proteome landscape. Moreover, MYC was predicted as inhibited, in agreement with the expected low 
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proliferation rate exhibited by differentiated 7-cells (Supp. Fig. 4a). Of note, three of the top upstream regulators 
(TP53, MYC and HNF4A) were predicted in the Top5 of all four effects, with the prediction of MYC inhibition 
being also a shared feature.
Figure 2. Global proteome analysis of hiPSC differentiating either on Matrigel or encapsulated in alginate 
capsules. (a) Scheme illustrating the cell populations and differentiation stages considered for global 
proteomics. (b) Experimental design of the conditions compared in TMT 11-plex proteomics. (c) Hierarchical 
clustering of normalized TMT-ratios (n = 2, 2, 2, 2, 3). (d) Analysis workflow depicting the comparisons 
employed and the assessed corresponding effect. (e) The number of proteins showing a dynamic of regulations 
compatible with an islet-promoting pattern in response to each of the four effects considered. Arrows depict 
the generic prerequisite direction of regulation for group inclusion. (f) Pies charts depicting the proportion 
of proteins following islet-promoting and islet-antagonizing regulation patterns in each of the four effects 
considered. The graph bars represent the proportion of proteins reaching abundance levels indistinguishable 
from those detected in native human islets.
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In addition, the protein set contained key markers of pancreatic-islet cells, such as the hormones GCG (gluca-
gon) and IAPP (Islet Amyloid Polypeptide, co-secreted with insulin by the β-cells), the hormone processing pro-
convertases PCSK1N and PCSK2 (alpha-cell marker) as well as the pan-endocrine marker CHGA (chromogranin 
A) (Fig. 3b).
Figure 3. Pathway analysis and heatmaps of proteins following islet-promoting regulation patterns in response 
to the different effects assessed. (a) Tables depicting the top canonical pathways and predicted upstream 
regulators in response to Differentiation Cocktail Effect, (b) Heatmap representing the regulation of selected 
markers in response to Differentiation Cocktail Effect (c) Tables depicting the top canonical pathways and 
predicted upstream regulators in response to Confounding Effect, (d) Heatmap representing the regulation 
of selected markers in response to Confounding Effect, (e) Tables depicting the top canonical pathways 
and predicted upstream regulators in response to Early Encapsulation Effect, (f) Heatmap representing the 
regulation of selected markers in response to Early Encapsulation Effect, (g) Tables depicting the top canonical 
pathways and predicted upstream regulators in response to Late Encapsulation Effect, (h) Heatmap representing 
the regulation of selected markers in response to Late Encapsulation Effect (orange A – predicted activation, 
blue I – predicted inhibition, red # signals shared pathways or predicted upstream regulators between left and 
right effects).
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The pathway analysis of the protein subset attaining abundance values similar to islets identified IGF-1 
Signaling as being the Top 3 canonical pathway and HNF4A as top predicted upstream regulator, suggesting 
that at least some of the markers governing islet cell differentiation reached the desired islet-like abundance 
(Supplemental Fig. 4b). Taken together, these results indicate an expected improved differentiation status of the 
cells following the addition of the differentiation cocktails. Of note, the action of the differentiation protocol cock-
tails seems to mostly promote α-cell fate markers, a problem already described by previous studies35.
For the Confounding Effect (i.e. the observed modulation of the proteins could not be unequivocally attrib-
uted to the differentiation cocktail, late encapsulation or both) the pathway analysis of the protein set exhibiting 
an islet-promoting pattern of regulation, revealed the involvement of the PI3K/AKT axis and mTOR signalling 
within the Top 5 canonical pathways (Fig. 3c). The proteome regulatory signature was consistent with the activa-
tion of important upstream regulators for pancreatic-islet differentiation such as SOX4 and MAF (Supp. Fig. 4c). 
Moreover, the Confounding effect prompted the islet-promoting regulation of all standard islet hormones, includ-
ing insulin, as well as key molecular components involved in β-cell function and generally in hormone synthesis 
and secretion (Fig. 3d). The analysis of the proteins reaching islet-abundance values identified similar canonical 
pathways, with seven of the top pathways involving components of PI3/AKT or mTOR signalling (Supp. Fig. 4d).
Interestingly, the Top 5 canonical pathways were overlapping with the Late Encapsulation Effect and partially 
overlapping with the Early Encapsulation Effect, with slight differences in rank (Fig. 3c,e,g). Moreover, the Early 
and Late Encapsulation effects share their prediction of Top 5 upstream regulators. Last, the Late Encapsulation 
Effect presents a similar regulation of all islet hormones (Fig. 3h). Overall, these data suggest that the encapsula-
tion and not the differentiation cocktail was the driving-force promoting the improved islet-signature regulation 
of the Confounding effect.
The pathway analysis of the encapsulation-based effects (Early and Late Encapsulation effects), showed a high 
degree of overlap for both the Top 5 canonical pathways and the Top 5 predicted upstream regulators (4/5), dis-
playing the involvement of the PI3K/AKT axis and mTOR Signalling as well as HNF4A and CST5 as top upstream 
regulators (Fig. 3e,g). The proteome signatures of both effects allowed the prediction of CDKN2A (p16) activation 
as well as MYC1 and FOXM1 inhibition, suggesting a decrease in the differentiating cell proliferation in response 
to encapsulation, regardless of the encapsulation stage (Supp. Fig. 4e,g).
Specific for the Early Encapsulation Effect, the proteome profile allowed the prediction of PDX1 activation as 
well as the inhibition of β-catenin (Supp. Fig. 4e), suggesting a differentiation event promoted by encapsulation 
during the early stages of differentiation. The Early Encapsulation Effect promoted the regulation of only one islet 
hormone, SST (somatostatin), as well as chromatin modifiers (such as EZH2) and β-cell differentiation factors, 
consistent with the early differentiation stage of these cells (Fig. 3f).
In contrast, the Late Encapsulation Effect induced the islet-promoting regulation of all pancreatic islet hor-
mones (Fig. 3h). Besides hormones, a large number of key factors involved in hormone synthesis and secretion 
were regulated towards islet-abundance values, including the main pancreatic islet-cells proconvertases PCSK1 
(β-cell marker) and the main glucose transporter in humans, GLUT1 (SLC2A1) (Fig. 3h). As expected, the anal-
ysis of the protein subset displaying islet-like abundance values reinforced the involvement of the PI3K/AKT axis 
and mTOR Signaling in addition to HNF4A as a top predicted upstream regulator (Supp. Fig. 4f,h).
In conclusion, the encapsulation during the late stages of differentiation promotes the pancreatic-islet differ-
entiated profile in S7-cells, exhibiting increased level of hormones and hormone proconvertases.
Overall, these results suggest that the Differentiation Cocktail Effect presented the most divergent signature of 
the protein set with islet-promoting regulation, while the three effects involving cell encapsulation exhibit rather 
related signatures. Moreover, the effect of encapsulation seems to have a stronger impact on the proteome profile of 
cells than the effect of the differentiation cocktail, as inferred from the Confounding Effect analysis. Last, the Early 
Encapsulation Effect seems to be able to promote early differentiation signals towards islet cell fate, while the Late 
Encapsulation effect promotes hormones and factors involved hormone synthesis and secretion, hence boosting 
the differentiated islet-cell profile.
Encapsulation and the differentiation cocktail promote different protein sets. To identify 
whether encapsulation acts on the same targets as the differentiation cocktail, we first filtered for proteins exhib-
iting islet-promoting regulation shared by Differentiation Cocktail Effect, Early Encapsulation Effect and Late 
Encapsulation Effect (Fig. 4a, left panel, Supp. Table 3). We identified only 210 proteins as being regulated by all 
three effects, representing 25.5%, 8.2% and 6.9% of the respective protein sets, with the pathway analysis retriev-
ing mainly metabolic pathways.
The same Venn comparison revealed 294 proteins being regulated exclusively by the Differentiation Cocktail 
and Early Encapsulation effects (Fig. 4a, middle panel, Supp. Table 3). In this subset, IPA identified Protein Kinase 
A Signalling as well as Tight Junction Signalling in the Top 5 canonical pathways, with the first being predicted 
as activated. The third group, solely regulated by the Differentiation Cocktail and Late Encapsulation effects, con-
tained 69 proteins (Fig. 4a, right panel, Supp. Table 3). The pathway analysis strength was limited due to the very 
low number of proteins in this profile; however it contained several key pancreatic-islet markers among which 
GCG, IAPP and CHGB (chromogranin B).
These data indicated that the encapsulation and the differentiation cocktail largely regulate different tar-
gets. The encapsulation during early stages of differentiation shared the largest number of proteins exhibiting 
islet-promoting regulation with the effect of the differentiation cocktail, suggesting once more that encapsulation 
alone can, at least in some extent, promote the pancreatic islet-cell differentiation. Furthermore, the boost of key 
mature islet-cell markers induced by the differentiation cocktail reinforces the role of encapsulation during the 
later stages of differentiation in boosting the differentiated islet-cell signature.
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Figure 4. Pathways analysis of proteins displaying islet-promoting regulation patterns in response to more 
than one effect. (a) IPA-generated tables of the Top 5 canonical pathways for proteome landscapes regulated 
in response to all three effects considered (purple, left Venn diagram) as well as to Differentiation Cocktail 
Effect and Early Encapsulation Effect solely (green, middle Venn diagram). Selected regulated pancreatic 
islet markers are shown for the proteome landscape responding to Differentiation Cocktail Effect and Late 
Encapsulation Effect solely (yellow, right Venn diagram). (b) IPA-generated tables of top canonical pathways 
and selected regulated pancreatic islet markers for proteome landscapes regulated by encapsulation regardless 
of differentiation stage of encapsulation (purple, left Venn diagram), only by encapsulation during the early 
stages (S0- > S5) of differentiation (green, middle Venn diagram) and only by encapsulation during the late 
stages (S5- > S7) of differentiation (yellow, right Venn diagram). (c) Selected IPA circular networks for the 
proteome regulated exclusively by either Early Encapsulation Effect (left) or Late Encapsulation Effect (right). 
The heatmap represents the direction of regulation towards islet-abundance values in S5bead[S0-S5] compared to S5 
(left) and S7bead[S5-S7] compared to S7 population. Orange A – predicted activation, blue I – predicted inhibition, 
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Encapsulation effects on differentiation are stage-specific. To compare further the Early and 
Late Encapsulation effects, we first performed pathway analysis on the shared group of proteins exhibiting 
islet-promoting regulation (Fig. 4b, left panel, Supp. Table 3). The two effects share a large battery of proteins 
(2048) accounting for 80.16% and 67.43% of the respective protein sets. Pathway analysis revealed the EIF2 
Pathway, RAR activation and mTOR Signaling as the Top 3 canonical pathways. Moreover, both effects collectively 
promoted towards islet-like levels several key pancreatic islet markers, including: the SST hormone, the FOXA2 
and GATA6 developmental factors (central role in early pancreatic islet-cell differentiation) and the epigenetic 
modifiers EZH2 (histone methyltransferase, a key regulator of β-cell proliferation and regeneration), HDAC1 
and HDAC7 (histone deacetylases with role in β-cell mass regulation). These results indicate that most of the 
proteins respond to encapsulation regardless of the encapsulation stage. Also, the presence of key pancreatic-islet 
epigenetic modifiers in this data set confirms once more the capacity of encapsulation to profoundly affect and 
promote islet-cell fate.
The pathway analysis of proteins exhibiting islet-promoting regulation triggered solely by early encapsulation 
(Fig. 4b, middle panel, Supp. Table 3) indicated PI3K/AKT axis as backbone of several top canonical pathways. 
The central role of AKT regulation towards islet abundance values was further illustrated by its central role in the 
IPA-generated circular networks.
The late encapsulation effect counterpart (Fig. 4b, right panel, Supp. Table 3) encompasses proteins involved in 
insulin receptor signalling, metabolic pathways and PPARα/RXRa activation, as well as differentiated pancreatic 
islet markers such as hormones (INS, GCG, PPY, IAPP) and critical components of the hormone processing and 
secretion (PCSK1, SYT7, IGF2BP3, IGFP5, amongst others). Late encapsulation also regulates epigenetic mod-
ifiers with known importance for islet cell fate, such as DNMT1 and DNMT3a. The regulation of DNMT1 was 
demonstrated previously to alter cell fate maintenance and to promote α-to-β-cell transdifferentiation36.
All these results suggest that encapsulation treatment is a driving force promoting β-cell fate by both promot-
ing differentiation at early stages and potentiating the differentiated islet signature during the last, confirming our 
initial IF results.
Pathway analysis is suggestive of encapsulation regulating the proteome landscape via integ-
rins. Last, we wanted to characterize the general effects and targets of encapsulation, independent of its action 
on promoting the pancreatic islet cell fate. For this purpose, we directly compared the encapsulated differentiating 
cells with their 2D differentiating counterpart (i.e. S5bead[S0-S5] vs S5 as well as S7bead[S5-S7] vs S7, Fig. 5a,e).
Despite a commonly reported encapsulation issue, neither of the encapsulation-based effects displayed 
a clear-cut molecular hypoxia fingerprint. In contrast with the typical hypoxia signature, the Glycolysis, 
Antioxidant and Hypoxia-related signalling were inferred as inhibited (Supp. Fig. 5a). Consistently, one of the 
key transducers of hypoxia, HIF1α (hypoxia-inducible factor 1a) was not detected as upregulated by neither 
proteomics nor RNAseq, while the overall molecular landscapes were predicted to be consistent with HIFα inhi-
bition (Supp. Figs. 5a and 6b red border). Nevertheless, the Oxidative Phosphorylation and TCA Cycle (Krebs 
Cycle) were reported as inhibited (Supp. Fig. 5a), which can be caused, amongst others, by hypoxia, thus a poten-
tial sub-standard oxygenation of these cells cannot be completely ruled out.
Moreover, the analysis revealed that, besides the already identified pathways involved in islet-cell fate differ-
entiation process, both effects induced the regulation of a wide range of pathways involving integrin signalling 
(Fig. 5, Supp. Fig. 5b–g, Supp. Table 4), including RhoGDI Signaling (Fig. 5a,b) and PTEN Signaling (Fig. 5a, 
Supp. Fig. 5b), that were predicted as upregulated, together with predicted downregulation of the PI3K/AKT 
pathway (Fig. 5a,c), the Integrin Signaling itself, (Fig. 5a,d), the Regulation of actin-based motility by RHO 
(Fig. 5a, Supp. Fig. 5c), and Actin Cytoskeleton Signalling (Fig. 5a, Supp. Fig. 5d). Interestingly, several of the 
pro-islet signatures identified above as characterizing the landscapes induced by the encapsulation effects, such as 
the PI3K/AKT axis or PTEN Signalling, are also shown to be regulated through integrins in our samples (Fig. 5c, 
Supp. Fig. 5b). Moreover, we also detected in the top pathways the growth regulating HIPPO pathway (predicted 
as activated) and the 14-3-3 Signalling pathway (predicted as inactivated) (Supp. Fig. 5e,f) characterized by YAP1 
downregulation upon encapsulation.
To further validate these results, we compared the above late encapsulation pathway analysis (S7bead[S5-S7] vs S7) 
and the pathways analysis performed on the differentially expressed genes (DEGs, FC ≥ 2, FDR < 0.05) identified 
by RNAseq (3′ RNA Transcriptomics) between the same sample conditions. The analysis revealed that the vast 
majority of the top activated/inhibited pathways (Fig. 4, Supp. Fig. 5b–f) and the top predicted upstream regula-
tors responsible for the observed landscapes exhibited the same inferred regulation (Supp. Fig. 6a,b). Moreover, 
key markers shared by several of the above identified pathways (Fig. 4, Supp Fig. 5b–f) presented similar observed 
regulation dynamic at protein and transcript level (Supp. Fig. 6c).
Overall, these results suggested that encapsulation acts during iPSC differentiation through integrins, which 
probably translate the pressure elicited by the confinement of cells in the alginate matrix into signalling cascades. 
Of note, these pathways patterns of regulation are consistent with previously published reports37, in which their 
involvement in promoting β-cell differentiation in a different system (micropatterned slides) was proposed, sug-
gesting a general role of the pressure-integrin axis in promoting cell differentiation in confined structures.
green – observed downregulation, red – observed upregulation. The circular networks and the top canonical 
pathways were generated through the use of IPA (QIAGEN Inc., https://www.qiagenbio-informatics.com/
products/ingenuity-pathway-analysis).
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Figure 5. Pathway analysis of the proteome landscape generated by the direct comparison between cells 
differentiating in alginate capsules and Matrigel differentiated-cells. (a) Analysis workflow and IPA-generated 
tables of the top canonical pathways predicted activated or inhibited at stage 5 of differentiation between 
S5bead[S0-S5] as compared and S5-cells. (b–d) IPA-generated graphical representation of RhoGDI signalling, PI3K/
AKT Pathway and Integrin Signalling, (e) Analysis workflow and IPA-generated tables of the top canonical 
pathways predicted activated or inhibited at stage 7 of differentiation between in S7bead[S5-S7] as compared and 
S7-cells (blue - predicted inhibited, orange – predicted activated, green – observed downregulation, red – 
observed upregulation, arrow heads point to integrin involvement, magenta # points at shared top pathways 
between the comparisons). The pathways were generated through the use of IPA (QIAGEN Inc., https://www.
qiagenbio-informatics.com/products/ingenuity-pathway-analysis).
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Discussion
Current in vitro differentiation protocols for the generation of insulin-producing cells from hPSCs, produce 
heterogeneous cell populations containing different progenitors and polyhormonal cells38,39 that show limited 
responsiveness to glucose challenges, and are therefore considered immature4,5. Nevertheless, transplanting 
encapsulated hiPSC-derived pancreatic endocrine cells into diabetic mice40–45 concludes the differentiation pro-
cess and generates functionally mature β-cells, able to maintain glucose homeostasis. The cellular and molecular 
basis of the in vivo process promoting the in vivo final β-cell maturation is not known, due to the complex set of 
systemic interactions acting on the transplanted encapsulated cells.
In this study, our main goal was to characterize the specific effects of the encapsulation on the differentiation 
potential by studying its impact on the differentiating cells proteome fingerprint during either early or late dif-
ferentiation. In order to eliminate any interference from a possible aggregation/cell clustering effect, we focused 
on the encapsulation of single cells. This is in contrast with previous studies, which deliberately used clusters to 
assess the alginate encapsulation effect29. Moreover, encapsulating single cells seems to apparently facilitate cell 
oxygenation as no clear signs of hypoxia were observed in contrast to the results reported for encapsulated islets 
or aggregates46–48.
We showed here for the first time that encapsulating single cells during pancreas endocrine differentiation 
promotes a large batch of proteins towards an islet-like proteome landscape, with the cells encapsulated during 
the later stages of differentiation exhibiting the nearest islet-like profile. Pathway analysis suggests that the effects 
of encapsulation are transduced via integrins, which translate the cell confinement into intracellular signalling. 
Of course, the significant islet-profile enhancement of the encapsulated differentiated cells does not imply a sig-
nificant improvement of their functionality. It is expected that acquiring this parameter still absolutely requires 
transplantation into living hosts and in vivo maturation, hence requiring further investigations.
Our IF results show that cells differentiating in alginate capsules for the entire length of differentiation dis-
play an increased percentage of glucagon- and somatostatin-expressing cells, however not insulin. Interestingly, 
our strategy of defining a narrower window of encapsulation only during the final stages of differentiation 
(S7bead[S5-S7]), i.e. from the pancreatic progenitor stage [S5] to maturing islet cell stage [S7]), revealed also a sig-
nificant increase in the fraction of insulin-expressing cells, clearly suggesting that the timing of encapsulation is 
decisive for improving hormone-expression. Moreover, our global proteome analysis also revealed that, at the late 
stages of Matrigel differentiation, the differentiation cocktails promote mostly glucagon expression, while their 
addition on encapsulated cells will promote all four main islet hormones (insulin, glucagon, somatostatin and 
PPY). Somatostatin expression is positively modulated regardless of the encapsulation timing, being the hormone 
with the earliest detected regulation. In contrast, in a different study29, late encapsulation of ESC-derived pancre-
atic progenitor clusters, failed to exhibit an increase in insulin expression, but only glucagon and somatostatin, 
probably due to the inherently different differentiation protocol employed.
The general impact of the 3D organization for the cell differentiation potential is also supported by the 
introduction of air liquid interface1 or suspension culture49 at the last stages of the differentiation protocols. 
Nevertheless, in these studies1,4,29, the changes in the culturing conditions were also combined with clustering of 
cells aimed at mimicking the in vivo developmental niche, hence it was not possible to systematically distinguish 
between the beneficial effects of the 3D environment and the ones of the intercellular interactions in the clusters.
Regardless of stage, encapsulation did not significantly decrease the fraction of polyhormonal cells; never-
theless, it improved the proportion of insulin-expressing cells co-expressing the key β-cell markers PDX1 and 
NKX6.1. This is an important result, as previous experiments have revealed that progenitor cells expressing PDX1 
and NKX6.1 are the source for functional beta-like cells50, while increasing evidence indicates that hPSC-derived 
polyhormonal cells give rise to glucagon-positive α-like cells7.
Our subsequent proteome analyses suggested that encapsulation strongly boosts β-cell fate in a stage-specific 
manner, by promoting early-stage differentiation and potentiating the islet signature during the later stages. To 
our knowledge, this is the first comparison by global proteomics of encapsulated and Matrigel differentiating cells. 
In differentiating encapsulated cells, a large batch of proteins is regulated towards islet cell fate with a significant 
fraction reaching abundance values similar with islet. We detected a high degree of overlap in the protein popu-
lations regulated by encapsulation during early and late differentiation, suggesting that these generally respond to 
3D culturing conditions independent of the differentiation stage. We further pinpointed the regulation of growth 
pathways such as the mTOR signalling, the involvement of the PI3K/AKT axis as well as the INSR signalling in 
response to encapsulation. The INSR regulatory network is regulated in response to encapsulation during late 
differentiation specifically, while the PI3K/AKT axis seems to be part of the pathways modulated mostly in cells 
encapsulated early during differentiation. The inferred regulatory dynamic of the vast majority of these signalling 
pathways was replicated at gene expression level, suggesting that the inherent few pattern discrepancies were 
probably caused by different half-lives between transcripts and proteins, miRNA intervention, delays between 
transcription and translation as well as other forms posttranscriptional regulation.
Moreover, it was demonstrated recently that cell confinement is mandatory for endocrine cell specification 
during development and it negatively regulates the activity of the mechanoresponsive transcription factor YAP1 
through a mechanism involving an integrin α5β1-triggered actin cytoskeleton remodelling (F-actin-YAP1-Notch 
mechanosignaling axis)37,51. Similar with these observations, our proteomics data revealed the downregulation of 
YAP1 in encapsulated cells, coupled with the predicted activation of the Hippo pathway and inactivation of 14-3-3 
signalling. Moreover, the pathway analysis on the proteome of cells encapsulated during both early and late dif-
ferentiation further revealed a large number of top pathways such as RhoGDI Signaling, PTEN Signaling, PI3K/
AKT Pathway, Regulation of Actin-Based Motility by RHO, Integrin Pathway, and Actin Cytoskeleton Signalling 
share an integrin-based regulation. These data suggest that encapsulation acts during hiPSC differentiation acts 
through integrins by transducing the pressure elicited by confining the cells into alginate matrix to islet-fate pro-
moting signalling cascades. Overall, our results further support the role of confinement and extracellular pressure 
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on positively modulating the differentiation profile of hiPSC. Moreover, we expect that our data will contribute 
to demultiplexing the intricate outcome of the in vivo environment following the transplantation of encapsulated 
cells, by helping to exclude the protein profiles characterizing the confinement effect inherent to encapsulation.
Materials and Methods
Cell sources. We used human induced pluripotent stem cells previously generated via episomal reprogram-
ming31 from skin fibroblasts collected from a healthy donor. Prior to starting in vitro differentiation, the hiPSCs 
line was enriched for SSEA4+ cells using magnetic beads (MACS Miltenyi Biotec), and tested negative for myco-
plasma. Human islets were obtained as previously52 described from one male and three female deceased donors 
(age 52–63).
In vitro differentiation. The normal healthy hiPSC line was differentiated as described previously31 follow-
ing a seven-stage differentiation protocol1 in planar culture conditions (on Matrigel-coated plates) up to stage 
S5 (pancreatic endocrine precursor) and/or stage S7 (maturing beta-cells). All conditions were initiated from 2 
million hiPSC (S0) which resulted in an average of ~13 million S5 cells and ~22 million S7 cells. From these, we 
encapsulated ~5 million cells at S5 and respectively S7 (Experimental design Suppl. Fig. 1b).
Encapsulation in alginate beads. We used ultra-pure LVG (70% G and 198 mPas) sodium alginate (batch 
#BP-0907-02, FMC BioPolymer AS NovaMatrix, Norway) for encapsulation of hiPSC (S0) and S5 cells. Cells were 
collected using TrypLE Select Enzyme (cat.#12563011, Thermo Fisher), and after viability check and cell count-
ing, were resuspended in 1.8% alginate in 0.3 M mannitol. The gel beads were formed by using an electrostatic 
bead machine (Nisco Engineering AG, Switzerland) having a potential difference of 7 kV at a flow of 10 mL/h, and 
by using a standard nozzle with flat cut tip with an inner diameter of 0.5 mm. Alginate beads were incubated for 
less than 10 min in gelling solution (50 mM CaCl2, 1 mM BaCl2 in 0.15 M mannitol, 10 mM HEPES, pH 7.2)53, 
and rinsed three times in DPBS. The beads were transferred to a 6 cm culture plate and differentiation protocol 
was continued as described (Suppl. Fig. 1b).
Cell viability and count. Viability and cell count were performed on NucleoCounter NC-200 (ChemoMetec, 
Denmark) using the Via1-Cassette (cat. no. SKU: 941-0012) with Reagent A100 (cat. no. SKU: 910-0003) and B 
(cat. no. SKU: 910-0002), as instructed in their protocol for the count of Aggregated Cells A100 and B Assay.
Beads processing and IF staining. Alginate beads containing hiPSC-derived cells were fixed in 4% PFA 
for 1 hour washed in DPBS. For cryosectioning, alginate beads were dehydrated in a sucrose gradient of 10, 
20, 30% sucrose. For embedding in Tissue Tek OCT compound (Sakura JP), the beads were placed central in 
a gelatine capsule (Sanivo Pharma AS) in a plastic mould and frozen. 10 μm sections were obtained by using 
a cryotome (Leica CM 1950, Leica, DE) and added on gelatine slides. For whole mount, a mean of ten alginate 
beads (n = 6–13) were stained and mounted for each IF staining combination. The following primary antibodies 
were used: mouse anti-insulin (1/500, I2018, Sigma-Aldrich), guinea-pig anti-porcine insulin (1/400, A056401-
2, Dako), mouse anti-porcine glucagon (1/1000, G2654, Sigma-Aldrich), rat anti-somatostatin (1/100, sc-47706, 
Santa Cruz), guinea-pig anti-PDX1 (1/500, ab47308, Abcam), rabbit anti-PDX1 (1/500, ab47267, Abcam) 
and rabbit anti-NKX6.1 (1/100, NBP1-82553, Novus). The following secondary antibodies were used: goat 
anti-guinea-pig A488, goat anti-mouse A546, chicken anti-rat A647, goat anti-mouse A488, goat anti-guinea-pig 
A647, donkey anti-rabbit A546, and goat anti-mouse A647. The secondary antibodies were all from Molecular 
Probes (dilution 1/500). DAPI (1/1000, D1306, Molecular Probes) was used to stain the nuclei. The samples 
mounted in Prolong Diamond Antifade Mountant Media (P36970, Life technologies). Image acquisition was 
performed using Andor Dragonfly confocal microscope.
Confocal imaging. Whole mount beads were imaged using the Andor Dragonfly 5050 (Andor Technologies, 
Inc) confocal microscope with an 20x dry objective (CFI Plan Apochromat Lambda 20 × ). Each bead was imaged 
with 3 × 3 fields of view, which covered the entire bead. The z-stack were acquired from the top of each bead, and 
100 steps of 4 μm with a total of 400 μm depth, which corresponded to the imaging depth. Each image was taken 
with a high speed iXon 888 Life EMCCD camera with 1024 × 1024 resolution. For nuclear imaging we used 
405 nm laser with intensity of 20–50% and an exposure time of 100–200 ms. For detecting proteins, laser 488, 
546, and 647 were used with laser intensity ranging from 5–20% and exposure time of 50–200, depending on the 
antibody.
Furthermore, whole mount and sectioned beads were pictured with a Leica SP5 confocal (Leica) using a 40x 
immersion objective.
Image processing and analyses. Imaris 9.1.2. (Bitplane AG) was used to analyse the immunofluorescence 
pictures. A surface mask was used on the DAPI signal, with filters on absolute intensity from 1200 or 1500 to max, 
quality of more than 100, and size between 150 μm and 10 000 μm with separation of nuclei in clusters of 8 μm 
in diameter. For the different proteins spot masking was used with quality of more than 100. The MatLab plugin 
“Find spots close to surface” within 1 μm was used to analyse only spots belonging to a nucleus, which removed 
the unspecific staining from the analysis. To find colocalizing spots the MatLab plugin “Find colocalizing spots” 
within 1 μm was used, which gave cells expressing two proteins.
Global proteomics analysis. Non-encapsulated hiPSC-derived cells were washed in DPBS and harvested 
with TrypLE™ Select Enzyme (1×) (12563011, Thermo Fisher Scientific), and collected by centrifugation. Human 
islets were processed as previously described31,54, more specifically here four islet samples representing 200 
handpicked equally-sized islets per donor (described above) were combined and mixed to make a homogenous 
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mixture, and 15 μg protein of the mix were divided into three separate samples for downstream TMT 11-plex 
analysis. Encapsulated cells were lysed directly in the alginate beads, in a buffer containing 8 M Urea, 200 mM 
EPPS pH8.5 and protease inhibitors (Roche complete with EDTA), and sonicated (30 seconds × 3 times at 30% 
power). Chloroform-Methanol precipitation was performed as previously described55. The protein concentration 
was measured by using a BCA protein assay kit. Samples containing an estimated amount of 15 µg of total protein 
were processed as described previously31,54.
RNA isolation. RNA was isolated from Human islets, Matrigel-differentiating and encapsulated cells using 
the Qiagen RNeasy kit protocol according to the kit protocol and as described in Chera et al.56. Before procedure 
the alginate capsules were snap freeze in the kit lysis buffer, without de-algination. RNA quality was assessed 
using a NanodropOne (Thermo Scientific, US), before the samples were shipped to Qiagen Next-Generation 
Sequencing Center (Hilden, Germany) for sequencing and analysis.
Next generation sequencing. a. 3′ RNA transcriptomics, UPX. For the 2D versus 3D comparison the 
library preparation was performed using the QIAseq UPX 3′ Transcriptome Kit (QIAGEN). A total of 10 ng 
purified RNA was converted into cDNA NGS libraries. During reverse transcription, each cell is tagged with 
a unique ID (up to 384 different IDs) and each RNA molecule is tagged with a unique molecular index (UMI). 
Then RNA was converted to cDNA. The cDNA was amplified using PCR. Library preparation QC was performed 
using TapeStation 4200 (Agilent) or Agilent Bioanalyzer. Based on quality of the inserts and the concentration 
measurements the libraries were pooled in equimolar ratios. The library pool(s) were quantified using qPCR. 
Subsequently, the library pool were then sequenced on a NextSeq500 sequencing instrument according to the 
manufacturer instructions. Raw data was de-multiplexed and FASTQ files for each sample were generated using 
the bcl2fastq software (Illumina inc.). FASTQ data were checked using the FastQC tool. Data analysis was per-
formed using the QIAGEN GeneGlobe bioinformatics tool.
Sequencing was performed on an Illumina NextSeq500 sequencer. Filtering and subsequent mapping was 
done using the QIAGEN GeneGlobe portal. Normalization of UMI counts and subsequent pairwise differen-
tial regulation analysis was done using DESeq2. Further functional analysis to infer biological insights from the 
significantly differentially regulated genes from the group comparisons was performed using Ingenuity Pathway 
Analysis (IPA).
b. mRNA Sequencing. Sequencing for 2D samples and human ilets was performed on an Illumina HiSeq2500 
sequencer. All analyses were carried out using CLC Genomics Workbench (version 12.0.2) and CLC Genomics 
Server (version 11.0.2). Human genome version: hg38, Annotation: ENSEMBL Homo_sapiens.GRCh38.97. 
Adapter and quality trimming was done by “Trim Reads” tool from CLC Genomics Workbench. Adapters arte-
facts were removed by identifying read-through adapter sequences. Further, reads were trimmed based on quality 
scores and ambiguous nucleotides, e.g. due to stretches of Ns. A maximum of 2 ambiguous nucleotides were 
allowed in a read. The QC reports were generated by “QC for Sequencing Reads” tool from CLC Genomics 
Workbench. Read mapping and gene quantification were done by “RNA-seq Analysis” tool from CLC Genomics 
Workbench. The Empirical analysis of gene expression data is implemented in Qiagen’s pipeline as the ‘Exact Test’ 
for two-group comparisons developed by Robinson and Smyth [Robinson and Smyth, 2008] and incorporated in 
the EdgeR Bioconductor package [Robinson et al., 2010]. The ‘Empirical analysis of DGE’ algorithm in the CLC 
Genomics Workbench is a re-implementation of the “Exact Test”.
The datasets discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus57 and are 
accessible through GEO Series accession number GSE141891 and GSE141309.
Data analysis. The mass spectrometry data were analysed as previously described31,54. Protein quantitation 
values were exported for further analysis in Microsoft Excel and GraphPad Prism (version 8). The dataset was 
uploaded to ProteomeXchange via the PRIDE partner repository with the dataset identifier PXd012704.
The hierarchical clustering was performed with GeneSpring 14.9.1 GX software (Agilent), with clustering on 
both entities and conditions by using Squared Euclidian distance metric and Ward’s linkage rule. The pathway 
analyses were generated by QIAGEN’s Ingenuity Pathway Analysis program (IPA®, QIAGEN Redwood City, 
www.qiagen.com/ingenuity)58 as previously described31,54, here using 35 molecules/network; 25 networks/analy-
sis for generating the interaction networks.
Statistical analysis. Statistical analysis on the proteomics data was tested using unpaired two-tailed 
Student’s t-test, and a p-value of ≤0.05 was considered significant. Two-way ANOVA with Tukey’s multiple com-
parisons test were used to compare between the groups for number of cells positive for the different markers by IF 
staining. This analysis was performed using GraphPad Prism v8.1.2.
Ethical statement. The reported experimental protocols were approved by the Regional Committee of 
Medical and Health Research Ethics, for hiPSCs (REK 2010/2295) and for human islets (REK 2011/426), and 
all methods were carried out in accordance with the Helsinki Declaration. Informed consent was obtained from 
relatives for organ donation and for its use in research (human islets).
Data availability
The materials, methods and data sets that support the findings of this study are available upon request from the 
corresponding author (S.C.).
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